Pero la mitad de los cánceres ya se curan, como repite sin cesar cualquier oncólogo. Y la guerra contra la otra mitad se está librando ahora mismo en dos frentes esenciales. Uno se refiere al tema eterno del diagnóstico precoz, que pese a sus orígenes prehistóricos no ha perdido un ápice de importancia en nuestros días. Y el otro es la genómica, el nuevo cuerpo de conceptos y tecnologías del ADN que está revolucionando la biología en su conjunto, y la investigación del cáncer en particular.
Myriad's HRD test is able to detect when a tumor has lost the ability to repair DNA damage and would therefore be more susceptible to the DNA-damaging classes of drugs. The test directly measures the end result of the loss of the DNA repair function regardless of the genomic causation. The HRD test is effective at detecting the loss of function irrespective of whether the defects in the genes involved in the DNA repair mechanism were caused by hereditary germ line mutations or somatic mutations accumulated during the patient's life.
Under the terms of the agreement, Myriad will assess HRD status in patients who have been treated with PM1183 in PharmaMar's Phase II clinical study. Utilizing this information, Myriad and PharmaMar will hope to garner more information surrounding the role of HRD status in PM1183 response.
Eso fue hace ocho años. Wagner, de 69 años de edad, es sobreviviente de cáncer de seno. Wagner, químico de orgánica sintética, comenta que pasó décadas de su carrera desarrollando métodos para el análisis de carcinógenos potenciales en el agua potable. Sabe que la ignorancia pudo haberlo matado, de manera que ahora habla a quien escuche sobre su experiencia. 
A midsize pharmaceutical company investing heavily in research and development, PharmaMar has the world’s largest marine organism library, with over 135,000 specimens, and owns over 1,800 patents issued or in process. To replace paper-based clinical trial processes, PharmaMar sought an EDC system that would be easy to use and streamline the availability of reliable trial data for analysis. Following a successful deployment of Medidata Rave® in 2012, PharmaMar decided to use Rave for all future trials. It also chose Medidata’s Safety Gateway and Medidata Coder® to swiftly capture and code safety data, and is evaluating other applications across the Medidata Clinical Cloud platform to help enhance trial efficiencies and decision making effectiveness. 
PharmaMar required a system that was compliant with industry standards, particularly CDISC data models, for easy integrations and data sharing with its other systems. With its commitment to the Medidata’s standards-based platform, PharmaMar is now leveraging Medidata’s knowledge transfer program to quickly take technology management in-house. 
ET-770 isolated from Ecteinascidia thurstoni was tested for its anoikis-sensitizing effect on H23 and H460 human lung cancer cells by 2,3-b-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide salt (XTT) assay. The levels of proteins being involved in anoikis of cells were determined by western blot analysis. 
The ambitious research project, with a budget of almost 11 million euros —8 of which were funded by the European Commission — and in which some twenty bodies from throughout Europe have been taking part, came to a satisfactory end, the majority complying with the aims set out at the beginning.
The aim of this phase I study was to identify a feasible dose and schedule for the combination of cisplatin and trabectedin. The regimen evaluated consisted of cisplatin at a fixed dose of 75Â mg/m2 1-hour intravenous (i.v.) infusion followed by escalating doses of trabectedin 3-hour i.v. infusion, both administered on day 1 every 3Â weeks (q3wks). Two dose-limiting toxicities (DLTs), grade 4 neutropenia longer than 7Â days duration and grade 3 vomiting despite standard antiemetic therapy, occurred at the starting dose of trabectedin (0.75Â mg/m2). The immediately lower dose (trabectedin 0.60Â mg/m2) was evaluated in a total of 8 patients; no DLTs occurred and this was declared the recommended dose (RD). The safety profile of the combination at this dose and schedule was consistent with the known side effects of each agent alone: nausea, fatigue, transient transaminase elevations and neutropenia. No new or unexpected adverse reactions were observed. Two partial responses were reported at the RD in patients with pretreated ovarian cancer. Comparison with population pharmacokinetic data suggests a PK interaction between trabectedin and cisplatin leading to increased plasma exposure of trabectedin in the first 48Â h, lower platinum clearance and longer half-life. 
In conclusion, although the trabectedin dose achieved with this combination was low (50Â % of single-agent when given q3wks), this day 1 q3wks trabectedin plus cisplatin combination showed a feasible administration, a tolerable safety profile and some antitumor activity.
06.03.2013 
OPTATIO (OPtimizing TArgets y Therapeutics n alto riesgo y refractan ryOmieloma múltiple) es un proyecto de la UE en el marco Programa 7 y reúne la experiencia de doce instituciones de Alemania, Austria, la República Checa, Italia, Hungría y España .
.... OPTATIO is pursuing a unique strategy to break through this protective shield to enable better cancer treatment. In so doing, marine-based active substances are proving to be particularly attractive candidates as through evolution they have proven their capacity to survive in the chemical battles against marine organisms. 
PM01183 esta en Ensayos Clinicos para el Tratamiento de Cáncer de Mama , Ovario , Pulmon , Pancreas , Leucemia , Colón ... De momento el ensayo más avanzado es el de Ovario en Pacientes Resistentes a Platinos . 
Edison analiza a la perfeccion lo que hay a fecha de hoy en la I+D para el Tratamiento de Ovario Resistente a los Platinos y además da los Resultados Globales que obtiene cada Farmaco :
Merck al firmar el acuerdo pago a Endocyte 120 Millones $$ y hay un monto de 880 Millones $$ a pagar conforme se obtengan pasos pactados en el acuerdo . Además, si vintafolide recibiera la aprobación normativa, Endocyte obtendrá una cuota del beneficio en Estados Unidos igual, así como una regalía de un porcentaje de dos dígitos en las ventas del producto en el resto del mundo. Endocyte ha retenido el derecho de co-promocionar vintafolide con Merck en EE.UU. y Merck tiene el derecho exclusivo de promocionar vintafolide en el resto del mundo. 
Asimismo destaca que PM01183 tendría los Resultados de la Fase II en Cáncer de Mama en el 2015 .